Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 18;192(4):745-747.
doi: 10.1093/bjd/ljae447.

Exploring the genetic driver events of eccrine poromas and porocarcinomas: a retrospective, cross-institutional study of 54 cases

Mark J Arends  1 , Martin Del Castillo Velasco-Herrera  2 , Saamin Cheema  2 , Kim Wong  2 , Jacqueline M Boccacino  2 , Ian Vermes  2 , Kirsty Roberts  2 , Elizabeth Anderson  2 , Michiel P J van der Horst, Nicolas de Saint Aubain, Ahmed K Alomari, Carlos Monteagudo, Steven D Billings, Derek Frew, Emily Clarke, William Merchant, Neil Rajan, Peter Ferguson, Carolin Mogler, Ingrid Ferreira  2 , Thomas Brenn, Louise van der Weyden  2 , David J Adams  2
Affiliations

Exploring the genetic driver events of eccrine poromas and porocarcinomas: a retrospective, cross-institutional study of 54 cases

Mark J Arends et al. Br J Dermatol. .

Abstract

We have comprehensively characterized the mutational landscape of eccrine poroma (EP) and eccrine porocarcinoma (EPC), uncovering novel molecular events and delineating different pathways of tumorigenesis underlying these tumours. EPs are driven largely by oncogenic fusion genes, whereas EPCs are driven largely by somatic mutations affecting various pathways, with a subset driven by fusion genes as the first oncogenic driver, and somatic mutations representing secondary events contributing to progression of the tumour. Fusion genes in EP predominantly involve YAP1, while those in EPC preferentially involve PAK gene family members.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: The authors declare no conflicts of interest.

References

    1. Harms PW, Hovelson DH, Cani AKet al. . Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations. Hum Pathol 2016; 51:25–31. - PubMed
    1. Bosic M, Kirchner M, Brasanac Det al. . Targeted molecular profiling reveals genetic heterogeneity of poromas and porocarcinomas. Pathology 2018; 50:327–32. - PubMed
    1. Denisova E, Westpahl D, Surowy HMet al. . Whole-exome sequencing in eccrine porocarcinoma indicates promising therapeutic strategies. Cancer Gene Ther 2022; 29:697–708. - PMC - PubMed
    1. Sekine S, Kiyono T, Ryo Eet al. . Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma. J Clin Invest 2019; 129:3827–32. - PMC - PubMed
    1. Kervarrec T, Westphal D, Pissaloux Det al. . Porocarcinomas with PAK1/2/3 fusions: a series of 12 cases. Histopathology 2024; 85:566–78. - PubMed

LinkOut - more resources